257 related articles for article (PubMed ID: 25359494)
21. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
[TBL] [Abstract][Full Text] [Related]
22. [Abnormal expression of APRIL in colorectal cancer cells promotes tumor growth and metastasis].
Wang GH; Lu MH; Wang JC; Wang F; Ding WF; Wang YG; Ju SQ; Wang HM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):249-55. PubMed ID: 23985251
[TBL] [Abstract][Full Text] [Related]
23. Correlation between
Aktar S; Islam F; Cheng T; Gamage SMK; Choudhury IN; Islam MS; Lu CT; Hamid FB; Ishida H; Abe I; Xie N; Gopalan V; Lam AK
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761948
[TBL] [Abstract][Full Text] [Related]
24. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
Vakil L; Najafipour R; Rakhshani N; Zamani F; Morakabati A; Javadi A
Tumour Biol; 2016 Jul; 37(7):8841-8. PubMed ID: 26749281
[TBL] [Abstract][Full Text] [Related]
25. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations.
Hammond DE; Mageean CJ; Rusilowicz EV; Wickenden JA; Clague MJ; Prior IA
J Proteome Res; 2015 Mar; 14(3):1535-46. PubMed ID: 25599653
[TBL] [Abstract][Full Text] [Related]
26. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
Al-Mulla F; Milner-White EJ; Going JJ; Birnie GD
J Pathol; 1999 Mar; 187(4):433-8. PubMed ID: 10398103
[TBL] [Abstract][Full Text] [Related]
27. Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.
Hayashi T; Yoshida Y; Yamada T; Tanaka K; Shimaoka H; Kajitani R; Munechika T; Nagano H; Matsumoto Y; Komono A; Sakamoto R; Aisu N; Yoshimatsu G; Yoshimura F; Hasegawa S
Cancer Med; 2022 Aug; 11(16):3126-3135. PubMed ID: 35312176
[TBL] [Abstract][Full Text] [Related]
28. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
PLoS One; 2016; 11(2):e0149099. PubMed ID: 26881434
[TBL] [Abstract][Full Text] [Related]
29. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract][Full Text] [Related]
30. KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
Kumar SS; Price TJ; Mohyieldin O; Borg M; Townsend A; Hardingham JE
Gastrointest Cancer Res; 2014 Jan; 7(1):23-6. PubMed ID: 24558511
[TBL] [Abstract][Full Text] [Related]
31. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
[TBL] [Abstract][Full Text] [Related]
32. KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer.
Choi SH; Kim JK; Chen CT; Wu C; Marco MR; Barriga FM; O'Rourke K; Pelossof R; Qu X; Chang Q; de Stanchina E; Shia J; Smith JJ; Sanchez-Vega F; Garcia-Aguilar J
Mol Cancer Res; 2022 Aug; 20(8):1305-1319. PubMed ID: 35394541
[TBL] [Abstract][Full Text] [Related]
33. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.
Wiersma VR; de Bruyn M; Wei Y; van Ginkel RJ; Hirashima M; Niki T; Nishi N; Zhou J; Pouwels SD; Samplonius DF; Nijman HW; Eggleton P; Helfrich W; Bremer E
Autophagy; 2015; 11(8):1373-88. PubMed ID: 26086204
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.
Liu X; Wang Y; Zhao J
Oncol Rep; 2017 Nov; 38(5):3187-3196. PubMed ID: 29048669
[TBL] [Abstract][Full Text] [Related]
36. Mutation of KRAS in colorectal adenocarcinoma in Greenland.
Mousavi N; Truelsen SLB; Bernth-Andersen S; Koch A; Heegaard S
APMIS; 2022 Aug; 130(8):493-497. PubMed ID: 35655437
[TBL] [Abstract][Full Text] [Related]
37. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.
Figueiredo ML; Stein TJ; Jochem A; Sandgren EP
Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894
[TBL] [Abstract][Full Text] [Related]
38. Different oncological features of colorectal cancer codon-specific
Ahn HM; Kim DW; Oh HJ; Kim HK; Lee HS; Lee TG; Shin HR; Yang IJ; Lee J; Suh JW; Oh HK; Kang SB
World J Gastroenterol; 2023 Aug; 29(32):4883-4899. PubMed ID: 37701134
[TBL] [Abstract][Full Text] [Related]
39. Lack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma.
Arndt A; Kraft K; Wardelmann E; Steinestel K
Biomed Res Int; 2015; 2015():185404. PubMed ID: 26106602
[TBL] [Abstract][Full Text] [Related]
40. Characterization of KRAS Mutational Regression in Oligometastatic Patients.
Ottaiano A; de Vera d'Aragona RP; Trotta AM; Santorsola M; Napolitano M; Scognamiglio G; Tatangelo F; Grieco P; Zappavigna S; Granata V; Perri F; Luce A; Savarese G; Ianniello M; Casillo M; Petrillo N; Belli A; Izzo F; Nasti G; Caraglia M; Scala S
Front Immunol; 2022; 13():898561. PubMed ID: 35936004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
